Israeli startup AccuLine has developed CORA, a deep learning-based system that enables early examination of coronary arteries and timely treatment initiation for patients.
Cardiovascular disease is the leading cause of death worldwide, and current diagnostic tools are often inaccurate, invasive, and not widely accessible. ECG tests lack precision, and procedures like cardiac CT or coronary angiography involve contrast agents and radiation exposure. These costly tests require long wait times, are only performed in well-equipped hospitals, and are often not covered by insurance unless the patient has clear symptoms or is in a high-risk group, making early diagnosis challenging.
AccuLine's CORA system offers a non-invasive, accurate test that can be conducted in a family doctor's office. Within minutes, the system analyzes three parameters: heart electrical function, oxygen saturation, and respiration. By combining noise-filtering methods with deep learning algorithms, CORA assesses the condition of a patient's coronary arteries, allowing for prompt treatment.
Moshe Barel, co-founder and CEO of AccuLine, states, "This test has the potential to save millions of lives annually and save health systems hundreds of millions of dollars on tests and expensive treatments for heart attack patients, including rehabilitation and medications."
According to "Kalkalist," the startup secured $4.2 million in seed funding, with support from the Israel Innovation Authority, the Google AI Startups Fund, and the Mayo Clinic.
